Harnessing Apoptosis in AML

Kapil Saxena; Courtney DiNardo; Naval Daver; Marina Konopleva

doi:10.1016/S2152-2650(20)30464-X

Harnessing Apoptosis in AML

Kapil Saxena, Courtney DiNardo, Naval Daver, Marina Konopleva

Leukemia

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML continues to be explored.

Original language	English (US)
Pages (from-to)	S61-S64
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
DOIs	https://doi.org/10.1016/S2152-2650(20)30464-X
State	Published - Sep 2020

Keywords

AML
BCL2
MCL1
synergy
venetoclax

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S2152-2650(20)30464-X

Cite this

@article{d2bcb5dcaa9343dd82f64018ea9f175f,

title = "Harnessing Apoptosis in AML",

abstract = "The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML continues to be explored.",

keywords = "AML, BCL2, MCL1, synergy, venetoclax",

author = "Kapil Saxena and Courtney DiNardo and Naval Daver and Marina Konopleva",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = sep,

doi = "10.1016/S2152-2650(20)30464-X",

language = "English (US)",

volume = "20",

pages = "S61--S64",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Harnessing Apoptosis in AML

AU - Saxena, Kapil

AU - DiNardo, Courtney

AU - Daver, Naval

AU - Konopleva, Marina

PY - 2020/9

Y1 - 2020/9

N2 - The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML continues to be explored.

AB - The treatment landscape for AML has grown significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent (HMA) or low-dose cytarabine (LDAC) was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in AML continues to be explored.

KW - AML

KW - BCL2

KW - MCL1

KW - synergy

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85089797689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089797689&partnerID=8YFLogxK

U2 - 10.1016/S2152-2650(20)30464-X

DO - 10.1016/S2152-2650(20)30464-X

M3 - Article

C2 - 32862872

AN - SCOPUS:85089797689

SN - 2152-2650

VL - 20

SP - S61-S64

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

Harnessing Apoptosis in AML

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this